Volume 14 Issue 10, October 2018

Cytoreductive nephrectomy is the current treatment paradigm for metastatic renal cell carcinoma (RCC). However, the introduction of targeted therapies has dramatically changed the treatment landscape and may limit the role of nephrectomy in this disease. The recent CARMENA trial supports initial medical treatment of patients with RCC and synchronous metastases.

Many considered the failure of the SYMPLICITY HTN-3 trial to represent the end of therapeutic renal denervation. However, promising preliminary data from the SPYRAL HTN-OFF MED study and more recently the SPYRAL HTN-ON MED and RADIANCE-HTN SOLO studies support the efficacy of this intervention for blood pressure lowering in patients with hypertension.

In this plenary Review, Hoste and colleagues describe the global epidemiology of acute kidney injury (AKI). The influence of modifiable and non-modifiable AKI risk factors, delayed diagnosis, variation in diagnostic criteria and disparities in access to health care are also discussed.

In this Review, Bonny and Firsov describe the circadian rhythmicity in various renal functions and how disruption or alteration of the circadian clock is associated with kidney dysfunction and disease.

This Review explores the mechanistic links underlying the associations between HLA and kidney diseases. The authors discuss how these links might provide insights into disease pathogenesis and describe the clinical implications of these insights.